



Global Action. Local Change.

KDIGO Controversies Conference on Onco-Nephrology

December 13-16, 2018

Milan, Italy

Kidney Disease: Improving Global Outcomes (KDIGO) is an international organization whose mission is to improve the care and outcomes of kidney disease patients worldwide by promoting coordination, collaboration, and integration of initiatives to develop and implement clinical practice guidelines. Periodically, KDIGO hosts conferences on topics of importance to patients with kidney disease. These conferences are designed to review the state of the art on a focused subject and to ask conference participants to determine what needs to be done in this area to improve patient care and outcomes. Sometimes the recommendations from these conferences lead to KDIGO guideline efforts and other times they highlight areas for which additional research is needed to produce evidence that might lead to guidelines in the future.

Background

In the 21st century, patients with malignancy make up a growing number of the subjects seen for nephrology consult and/or critical care nephrology services. The outstanding progress in the therapy of malignancy presents new possibilities and challenges for both nephrologists and medical oncologists. It is important for nephrology services to be acknowledged and to take an active participation in the care of oncology patients. In addition, nephrology services need to better understand the biology of advanced malignancies and their treatment in order to become a valuable part of the teams working to yield the best possible outcome for cancer patients.

The links between kidney disease and malignancy were observed quite some time ago. However, it was only recently that their importance was recognized and a new subspecialty in nephrology, namely 'onco-nephrology' was established [1]. Chronic kidney disease (CKD) is often diagnosed in the general population [2], however, its incidence and prevalence among patients with different malignancies is not extensively studied and data are limited. Half a century ago, increased incidence of cancer in CKD



patients was discussed by Sutherland *et al.* [3] and other reports also linked CKD with an increased incidence of cancer [4-10].

A plethora of renal problems may be found in patients with malignancy. They may influence not only their short-term outcomes but also the adequate treatment of the underlying oncological disease. Thus, all kidney-related issues pose an important challenge for both oncology and nephrology specialities. Indeed, the incidence rates for many malignancies are increased and the amelioration in cancer mortality, due to more effective chemotherapy including targeted drugs and treatment with stem cells, has resulted in a rise in the cancer survivors' population [12]. Some of these survivors develop acute kidney injury (AKI) or CKD due to either the cancer itself and/or its therapy [13]. The kidneys may thus be directly or indirectly damaged by the malignancy or by one or more of the novel therapeutics that prolong lives, however at the cost of developing AKI or CKD.

In addition, multiorgan failure may be also seen in cancer patients. As a consequence, they may require intensive care unit (ICU) care and kidney replacement therapy (KRT). In the setting of advanced malignancy complicated by multiorgan illness, the appropriateness of aggressive treatment in "futile situations" and the role of palliative therapy remains an open question. Thus, the care for oncology patients has become more specialized and complicated, requiring collaboration among nephrology, medical oncology, critical care, and palliative care. The question of persistent therapy (e.g., continuation of KRT in advanced malignancy) vs. end-of-life care is also one that more clinicians are facing today.

Relevance of the topic and the conference

The prevalence of both cancer and kidney disease is high and as such it requires awareness from both oncologists and nephrologists concerning new cancer treatments and their potential adverse effects on kidney function. Therefore, the necessity of such multidisciplinary experts calls for the need of a new subspecialty field of onconeurology.



Increased incidence of CKD, in particular in the elderly, is of utmost concern. Many antineoplastic agents are cleared primarily by the kidneys as unchanged drugs or active metabolites. Therefore, a decline in kidney function can potentially lead to alterations in pharmacokinetics, resulting in elevated blood levels of the drugs and increased toxicity. It has been shown that a remarkable number of CKD subjects treated with chemotherapy require dose reduction in case of CKD, but they are not administered the appropriate adjusted dose [14]. Thus, it should be stressed that CKD is an under-recognized problem in the oncology population and estimated glomerular filtration rate is to be assessed simultaneously, not only in oncology wards but also in every department. This is due to the fact that patients are getting older, exhibit more comorbidities, are administered with more potentially nephrotoxic drugs and undergo more potentially nephrotoxic procedures such as percutaneous coronary interventions or CT with intravenous contrast agents etc. [15] It is of paramount importance to be aware of the kidney function in patients receiving potentially nephrotoxic agents and to monitor their kidney function regularly before each course of chemotherapy. Oncologists should adjust the dose of cytotoxic drugs according to actual kidney function. Especially in CKD patients with impaired kidney function treated with nephrotoxic chemotherapeutic agents, concomitant drugs should be carefully evaluated (e.g., NSAIDs). They should be avoided, if possible, as they may contribute to the nephrotoxicity of chemotherapeutics.

Conference Overview

To this end, this KDIGO conference on onco-nephrology will gather a global panel of multidisciplinary clinical and scientific expertise (e.g., nephrology, oncology, intensive care, hematology, pharmacology, etc.) that will identify key management issues in nephrology relevant to patients with malignancy. It is understood that the development of newer and more effective cancer treatments has led to an increasing number of cancer survivors but unfortunately many of these treatments can also be nephrotoxic. Therefore, prevention, early detection, long-term monitoring and treatment of ensuing problems in these patients is a growing need in this population.



The objective of this conference is to highlight the need to prevent or slow kidney damage due to various treatment therapies and to assess our current state of knowledge related to AKI and CKD arising from various malignancies (e.g., hematological cancers such as multiple myeloma and solid-organ cancers) including the management of cancer after kidney transplantation. Care for oncology patients has become more specialized and complicated, requiring collaboration among nephrologists, oncologists, intensivists, and palliative care specialists. The remarkable advances in cancer management present new opportunities and complex challenges for the oncology and nephrology communities. It is essential for nephrologists to be informed and actively involved in certain facets of cancer care; a better understanding of the rapidly evolving field of cancer biology and its therapy is required for nephrologists to become valuable members of the cancer care team and to provide the best nephrology care possible.

Drs. Jolanta Małyszko (Warsaw Medical University, Warsaw Poland) and Camillo Porta (IRCCS San Matteo University Hospital Foundation, Pavia, Italy) will co-chair this conference. The format of the conference will involve topical plenary session presentations followed by focused discussion groups that will report back to the full group for consensus building. Invited participants and speakers will include worldwide leading experts who will address key clinical issues as outlined in the **Appendix: Scope of Coverage**. The conference output will include publication of a position statement that will help guide KDIGO and others on therapeutic management and future research in this area.

References

1. Salahudeen AK, Bonventre JV. Onconephrology: the latest frontier in the war against kidney disease. *J Am Soc Nephrol.* 2013; 24: 26-30.
2. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, Salive M, Jones CP, Agodoa LY. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. *Am J Kidney Dis.* 1998; 32: 992-9.



3. Sutherland GA, Glass J, Gabriel R. Increased incidence of malignancy in chronic renal failure. *Nephron*. 1977; 18: 182-4.
4. Denker B, Robles-Osorio ML, Sabath E. Recent advances in diagnosis and treatment of acute kidney injury in patients with cancer. *Eur J Intern Med*. 2011; 22: 348-54.
5. Lameire N, Van Biesen W, Vanholder R. Electrolyte disturbances and acute kidney injury in patients with cancer. *Semin Nephrol*. 2010; 30: 534-47.
6. Salahudeen AK, Doshi SM, Pawar T, Nowshad G, Lahoti A, Shah P. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. *Clin J Am Soc Nephrol*. 2013; 8: 347-54.
7. Samuels J, Ng CS, Nates J, Price K, Finkel K, Salahudeen A, Shaw A. Small increases in serum creatinine are associated with prolonged ICU stay and increased hospital mortality in critically ill patients with cancer. *Support Care Cancer*. 2011; 19: 1527-32.
8. Janssen-Heijnen ML, Maas HA, Houterman S, Lemmens VE, Rutten HJ, Coebergh JW. Comorbidity in older surgical cancer patients: influence on patient care and outcome. *Eur J Cancer*. 2007; 43: 2179-93.
9. Hunter C, Johnson K, Muss H, Satariano W. Comorbidities and cancer. In: Hunter C, Johnson K, Muss H, editors. *Cancer in the Elderly*. New York: Dekker, M; 2000. p. 477-500.
10. Yung KC, Piccirillo JF. The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer. *Arch Otolaryngol Head Neck Surg*. 2008; 134: 1045-9.
11. Cengiz K. Increased incidence of neoplasia in chronic renal failure (20-year experience). *Int Urol Nephrol*. 2002; 33: 121-6.



12. National Cancer Institute. Surveillance Epidemiology and End Results: SEER stat fact sheets: All sites. Available at: <http://seer.cancer.gov/statfacts/html/all.html>. Accessed January 16, 2017.
13. National Cancer Institute: Find cancer statistics. Available at: www.cancer.gov/statistics/find. Accessed May 16, 2018.
14. Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, Wynendaele W, Canon JL, Lybaert W, Nortier J, Deray G, Wildiers H. Cancer and renal insufficiency results of the BIRMA study. *Br J Cancer*. 2010; 103: 1815-21.
15. Abujudeh HH, Gee MS, Kaewlai R. In emergency situations, should serum creatinine be checked in all patients before performing second contrast CT examinations within 24 hours? *J Am Coll Radiol*. 2009; 6: 268-73.



APPENDIX: SCOPE OF COVERAGE

Breakout Group 1: Kidney Problems in Hematology

1. How do we recognize and prevent tumor lysis syndrome? What renal testing/investigations should patients scheduled to initiate chemotherapy have?
2. Is there a role for total plasma exchange in the management of multiple myeloma cast nephropathy? How do we manage MM-related bone disease? How does one decide on bisphosphonate or denosumab therapy? How do we minimize risk of ESRD in MM?
3. How do we optimally manage calcineurin inhibitors in the recipients of allogeneic stem cell transplant?
4. Is a renal biopsy required to initiate chemotherapy in suspect immunoglobulin cast nephropathy?
5. Which patients with monoclonal gammopathy of renal significance should be offered treatment?
6. When are patients with myeloma and amyloidosis on dialysis candidates for kidney transplantation?
7. What is the appropriate chemotherapy selection for treatment of monoclonal gammopathy of renal significance?
8. What is the optimal dosing of cytotoxic agents in patients with CKD G3b-G5D?
9. What are the roles of high cutoff membranes and new sorbent devices (CytoSorb) in HSCT patients?
10. In patients with cancer related pain what analgesics are appropriate for long term management?
11. Which hematological cancer patients with CKD can be treated with erythropoietin-stimulating agents (ESAs)?



12. To dialyse or not: Is withholding dialysis a valid treatment option for hematological cancer patients and when is it the optimal time to initiate dialysis?

Breakout Group 2: Kidney Impairment and Solid-Organ Malignancies

Assessment of kidney function

1. What is the epidemiology of CKD in solid-organ tumors?
2. Which are the main pathophysiologic causes and mechanisms of kidney impairment in solid-organ tumors?
3. How is kidney impairment (GFR and biomarkers of cell damage) best measured in cancer patients?

Applicability & efficacy of various diagnostics

4. What are the key renal investigations for patients with solid-organ malignancy?
Consider:
 - a. At cancer diagnosis
 - b. During oncological treatment
 - c. During follow-up
5. Cancer screening in dialysis patients: Under which circumstances is it indicated? When it is, which exams should be done and how often?
6. Cancer screening in patients with glomerulopathies: When and how should it be done? (Consider membranous nephropathy and other possible paraneoplastic glomerulopathies)
7. When is a kidney biopsy indicated in cancer patients with urinary abnormalities?

Prevention of AKI & CKD or their progression

8. Should ACE inhibitors/ARBs be used for slowing kidney disease progression in CKD and/or nephrectomized cancer patients?



9. Is prevention of post-surgical AKI different in cancer patients compared to non-cancer surgery?
10. Is contrast-induced AKI a relevant issue in cancer patients? Should CKD patients with cancer receive fewer contrast media CT scans? How can contrast induced AKI be prevented in CKD patients with cancer?

Managing renal toxicities from treatments

11. What are the nephrotoxicities of various oncological treatments (e.g., chemotherapy, radiotherapy, targeted therapies, immunotherapy, bone targeting agents)?
12. ESA and iron therapy in CKD patients with solid-organ malignancies: Are the indications for treatment any different than those of CKD patients without malignancy? What is the appropriate hemoglobin target? What ESA dose should be considered? Which are the effects of iron and ESA treatments on survival in cancer patients?
13. Which are the optimal timing and the necessary dose adjustments of anticancer drugs in patients with CKD stage 3 to 5D? Does the dialysis regimen affect dosing of anti-cancer drugs?

Ethics

14. To dialyse or not: Is withholding dialysis a valid treatment option for solid-organ cancer patients and when is it the optimal time to initiate dialysis?

Breakout Group 3: Management and Treatment of Kidney Cancer

Epidemiology, prevalence, type of renal cell carcinoma (RCC)

1. Has the epidemiology of RCC changed in recent years?
2. What are the histological subtypes of RCC and underlying molecular characteristics?

Kidney function in RCC

3. What are the risk factors for impaired kidney function in RCC?
4. Is CKD as a risk factor and/or prognostic factor for RCC? If CKD is a risk factor, at what stage of CKD is a risk factor (e.g., ESKD)?
5. How can we optimize treatment of cancer patients on dialysis and renal dysfunction with tyrosine kinase and checkpoint inhibitor therapies?

Type of surgery (e.g., nephron sparing, nephrectomy) and its effect on kidney outcomes

6. Who are candidates for nephron-sparing surgery?
7. What is the role of cytoreductive nephrectomy in metastatic RCC (mRCC)?

New targeted therapies and renal side effects

8. What are the classes of targeting agents in the treatment of mRCC and their impact on the outcome of RCC?
9. What are the most frequent side effects of targeting agents in the context of renal toxicity and how can one ameliorate them?
10. Can we overcome underrepresentation of patients with CKD in cancer trials? What is the real-world evidence on efficacy and toxicity in these populations?

Follow-up after surgery (urologist, oncologist, nephrologist or dedicated team)

11. What is the role of adjuvant systemic therapy in high-risk localized RCC?
12. Can we predict and prevent changes in renal function-CKD following surgery?



Breakout Group 4: Malignancy and Kidney Transplantation

Epidemiology

1. What is the incidence, cancer risk factors and mortality rates of cancers in kidney transplant recipients compared with the general population?

Donor-derived cancers

2. What is the incidence of donor-derived malignancy in kidney transplant recipients and how may these risks differ by cancer types?

3. In what circumstances can a donor with active or historical neoplasia be accepted for donation?

4. What are the current strategies for reporting, screening, management, of those at risk and had acquired the disease after donor transmission of cancer has occurred?

5. What are the short- and longer-term outcomes of recipients who developed a donor-derived cancer?

Recipients with a prior cancer history

6. In patients with a prior cancer history, what are the eligibility criteria for transplantation?

7. What is the risk of cancer recurrence and the prognosis of those with recurrence?

8. What are some of the methods we could use to predict and prognosticate cancer recurrence in at risk patients?

Cancer screening in kidney transplant recipients

9. Should cancer screening in kidney transplant recipients differ from that implemented in the general population?

10. In addition to the standard population cancer screening tests suggested in the general (for breast, colorectal and cervical cancer), should routine screening/monitoring be suggested for other cancers such as renal cell carcinoma, PTLN and lung cancer?



11. What is the role of education in cancer protection?

Management of cancer after kidney transplantation

12. Are there any differences and limitation in diagnostics of cancer in kidney transplant recipients (e.g., role of biomarkers, imaging, biopsies, etc.)?

13. What are the methods to assess graft function and prevent AKI/progression of CKD in kidney transplant recipients when on anticancer therapy (chemo, radio, targeted/immunomodulatory therapies)? For example, the risk of acute rejection in the context of CTL4 and PD1 inhibitors.

14. What are the limitations in cancer therapy in kidney transplant recipients?

15. What are the optimal strategies for managing a transplant recipient with cancer before and after transplantation as far as the doses and types of immunosuppression are concerned? How do cancer treatments (e.g., chemotherapy, radiation, targeted therapies) impact immunosuppression strategies?